Evidence map›Paper›PMID 28790109›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.

Mohammed Kashani-Sabet, Mehdi Nosrati, James R Miller, Richard W Sagebiel, Stanley P L Leong, Andrew Lesniak, Schuyler Tong, Sandra J Lee, John M Kirkwood

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammed Kashani-SabetCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California. kashani@cpmcri.org.
Mehdi NosratiCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California.
James R MillerCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California.
Richard W SagebielCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California.
Stanley P L LeongCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California.
Andrew LesniakDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Schuyler TongCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California.
Sandra J LeeDana-Farber Cancer Institute, Boston, Massachusetts.
John M KirkwoodECOG-ACRIN Melanoma Committee, Philadelphia, Pennsylvania.

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1M
NCI NCTN-Network Lead Academic Site at UPCIU10CA180844 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRUFSKY, ADAM M, EDWARDS, ROBERT PAGE · 2014 to 2018
$4.5M
Validation of Genomic Targets in MelanomaR01CA114337 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KASHANI-SABET, MOHAMMED · 2005 to 2015
$3.2M
PHIP as a Biomarker of Triple-Negative MelanomaR01CA175768 · NCI · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI KASHANI-SABET, MOHAMMED · 2014 to 2017
$1.7M
NCI NIH HHS R01 CA114337NCI NIH HHS R01 CA175768NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180844NCI NIH HHS U24 CA196172
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorAdultAgedAntineoplastic AgentsCell Line, TumorCutaneous Malignant MelanomaFemaleHumansInterferon-alphaInterferon alpha-2Kaplan-Meier EstimateMaleMelanomaMiddle AgedNeoplasm GradingNeoplasm MetastasisAntineoplastic AgentsBiomarkers, TumorInterferon-alphaInterferon alpha-2NCOA3 protein, humanNuclear Receptor Coactivator 3OsteopontinRecombinant ProteinsRGS1 protein, humanRGS ProteinsSPP1 protein, human

Identifiers

PMID28790109
PMCPMC5690823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.